Middle East Pharmaceutical Industries Company SJSC

The company maintains a strong liquidity position, with a current ratio of 3.13, indicating that it has more than three times the current assets to cover its current liabilities. However, the liquidity risk is rated as medium, and the company has a negative net cash position after subtracting total debt, which could pose a challenge in the short term. The debt-to-equity ratio is 0.15, suggesting a relatively low level of leverage compared to the industry median, which is typically higher for pharmaceutical companies due to the capital-intensive nature of R&D and production.

In terms of profitability, the company's return on equity (ROE) is 23.31%, and its return on assets (ROA) is 16.18%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures are well above the industry median for pharmaceutical companies, which typically range between 10% and 15% for ROE and 5% to 10% for ROA, indicating that the company is outperforming its peers in terms of profitability.

The company's revenue is primarily concentrated in the domestic market, with no significant geographic diversification reported in the available data. This concentration could expose the company to regional economic and regulatory risks, which is a concern given the geopolitical volatility in the Middle East. The company's growth trajectory is expected to remain stable, with no significant revenue growth projected in the next fiscal year. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on new capital projects, which could be a sign of a mature business with limited expansion opportunities.

The risk assessment indicates a low potential for dilution, with no significant dilution sources identified in the recent filings or transcripts. However, the company's liquidity risk remains a concern due to the negative net cash position after subtracting total debt. The company has not issued any recent press releases or filed any significant regulatory documents that would indicate a major change in its business strategy or financial position.